Patients were randomized to receive either rhIL-1ra ( 100 mg ) or placebo ( vehicle ) by intravenous bolus , followed by a 72-hr continuous intravenous infusion of either rhIL-1ra ( 2.0 mg/kg/hr ) or placebo .
